eGenesis

32 articles about eGenesis

• eGenesis Presents New Data on Long-Term Survival in Preclinical Kidney Xenotransplantation at American Transplant Congress 2023

  6/5/2023

  eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, will present new data during the American Transplant Congress 2023, held June 3 – June 7, 2023 in San Diego, CA.

• Karius and eGenesis partner to help accelerate xenotransplantation for patients in need of organ transplants

  4/11/2023

  Karius® and eGenesis, Inc. a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced a partnership through which the two companies will develop infectious disease diagnostics for xenotransplantation initially from porcine to primates and ultimately to humans. 

• eGenesis Announces Knut Niss as Chief Technology Officer

  1/24/2023

  eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer.

• eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies

  1/9/2023

  eGenesis, Inc. (“eGenesis”) and Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that they have entered into a collaborative research agreement under which eGenesis will gain access to Eledon’s anti-CD40L antibody candidate, tegoprubart, for eGenesis’ ongoing preclinical research and development studies of human-compatible organs and cells for the treatment of organ failure.

• 

  BioSpace Movers & Shakers: John Maraganore, Larry Alstiel, Brad Margus and More

  4/22/2022

  Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

• eGenesis Promotes Michael Curtis, Ph.D., to Chief Executive Officer

  4/19/2022

  eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced the promotion of Michael Curtis, Ph.D., to Chief Executive Officer (CEO).

• 

  BioSpace Movers & Shakers, April 8

  4/8/2022

  Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week.

• eGenesis Appoints Eliezer Katz, M.D., FACS, as Chief Medical Officer

  4/4/2022

  eGenesis today announced the appointment of Eliezer Katz, M.D., FACS, as Chief Medical Officer (CMO).

• eGenesis Announces Research Collaboration with the University of Miami to Evaluate Human Compatible Islet Cells in Diabetes Model

  3/9/2022

  eGenesis, a gene-editing company developing human-compatible (HuCo™) organs and cells, today announced the initiation of a research collaboration with the University of Miami Leonard M. Miller School of Medicine.

• eGenesis Appoints Bradford Smith as an Independent Member of Its Board of Directors

  6/9/2021

  eGenesis announced the appointment of accomplished financial executive, Bradford Smith, Chief Financial Officer of Homology Medicines, Inc., as an independent member of the Board of Directors.

• eGenesis Expands Research Collaboration with Leading Academic Medical Center

  4/1/2021

  eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the expansion of a research collaboration with Duke University School of Medicine.

• 

  BioSpace Movers & Shakers, March 5

  3/5/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• eGenesis Appoints Veteran Financial Executive, Sapna Srivastava, Ph.D., as Chief Financial Officer

  3/4/2021

  eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the appointment of Sapna Srivastava, Ph.D., as Chief Financial Officer.

• 

  eGenesis Snags $125 Million for Cross-Species Organ Transplantation Tech

  3/2/2021

  Xenotransplantation company eGenesis raised $125 million in a Series C financing round to drive the company’s lead programs in kidney and islet cell transplant into the clinic. 

• eGenesis Announces $125 Million Series C FinancingProceeds will advance two lead xenotransplantation programs in kidney failure and type 1 diabetes into first-in-human studies

  3/2/2021

  eGenesis, a gene-editing and genome-engineering company developing human-compatible organs, tissues, and cells, today announced the successful completion of a $125 million Series C financing

• eGenesis Announces Research Collaboration with Leading Academic Medical CenterPartnership enables eGenesis’ genome engineering and transgenic production capabilities to conduct in vivo testing of pancreatic islet cell xenotransplants

  11/5/2020

  eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage, today announced the initiation of a research collaboration with Duke University School of Medicine. The collaboration will encompass evaluation of gene-edited pancreatic islet cells in non-human primate recipients as a prerequisite to advancin

• 

  BioSpace Movers & Shakers, Sept. 4

  9/4/2020

  Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.

• eGenesis Appoints Veteran Biotechnology Development Executive, Michael Curtis, Ph.D., as President of Research & Development

  9/1/2020

  eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage crisis, today announced the appointment of Michael Curtis, Ph.D., as President of Research & Development (R&D

• eGenesis Appoints Accomplished Biopharmaceutical Executive, Peter Hanson, DVM, Ph.D., as Chief Operating Officer

  7/1/2020

  eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage, today announced that Peter Hanson, DVM, Ph.D., has been appointed as Chief Operating Officer (COO). Dr. Hanson will assume responsibility for directing eGenesis’ day-to-day organizational and operational activities including production and man

• eGenesis Expands Research Collaboration with Massachusetts General Hospital

  6/2/2020

  Research collaboration will conduct in vivo testing of lead kidney and islet xenotransplant programs and validate platform in other organs